T-reg function changes: a novel immune regulatory effect underlying benefit of statin use on lethal prostate cancer

Sponsor:

National Cancer Institute

Sponsor Study ID:

R00CA246097

CTO #:

103472

NCT Number:

NCT05586360

Phase:

II

Protocol Type:

Treatment

Age Group:

Adults

Disease Sites:

Prostate

Study Objectives:

To evaluate whether men diagnosed with localized prostate cancer randomized to receive a statin prior to prostatectomy have greater intraprostatic YAP-mediated T-reg dysfunction compared to men randomized to the control group. To determine whether men randomized to the statin group have greater YAP-mediated T-reg dysfunction compared to men randomized to the control group restricting to tumor-infiltrating T-regs only. To determine whether men randomized to the statin group have greater YAP-mediated T-reg dysfunction compared to men randomized to the control group restricting to the subset of T-regs in the adjacent normal and stromal tissue area. To determine whether men randomized to the statin group have greater intraprostatic anti-tumor immune response compared to men randomized to the control group.

eConsent:

Not available

Study Documents:

Open Study Documents
(MUSC NetID required for document access)